IBDEI2TX ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,47489,1,4,0)
 ;;=4^C84.15
 ;;^UTILITY(U,$J,358.3,47489,2)
 ;;=^5001636
 ;;^UTILITY(U,$J,358.3,47490,0)
 ;;=C84.16^^209^2346^458
 ;;^UTILITY(U,$J,358.3,47490,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47490,1,3,0)
 ;;=3^Sezary Disease,Intrapelvic Nodes
 ;;^UTILITY(U,$J,358.3,47490,1,4,0)
 ;;=4^C84.16
 ;;^UTILITY(U,$J,358.3,47490,2)
 ;;=^5001637
 ;;^UTILITY(U,$J,358.3,47491,0)
 ;;=C84.17^^209^2346^461
 ;;^UTILITY(U,$J,358.3,47491,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47491,1,3,0)
 ;;=3^Sezary Disease,Spleen
 ;;^UTILITY(U,$J,358.3,47491,1,4,0)
 ;;=4^C84.17
 ;;^UTILITY(U,$J,358.3,47491,2)
 ;;=^5001638
 ;;^UTILITY(U,$J,358.3,47492,0)
 ;;=C84.18^^209^2346^460
 ;;^UTILITY(U,$J,358.3,47492,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47492,1,3,0)
 ;;=3^Sezary Disease,Mult Site Nodes
 ;;^UTILITY(U,$J,358.3,47492,1,4,0)
 ;;=4^C84.18
 ;;^UTILITY(U,$J,358.3,47492,2)
 ;;=^5001639
 ;;^UTILITY(U,$J,358.3,47493,0)
 ;;=C84.19^^209^2346^454
 ;;^UTILITY(U,$J,358.3,47493,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47493,1,3,0)
 ;;=3^Sezary Disease,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,47493,1,4,0)
 ;;=4^C84.19
 ;;^UTILITY(U,$J,358.3,47493,2)
 ;;=^5001640
 ;;^UTILITY(U,$J,358.3,47494,0)
 ;;=C84.40^^209^2346^441
 ;;^UTILITY(U,$J,358.3,47494,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47494,1,3,0)
 ;;=3^Peripheral T-Cell Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,47494,1,4,0)
 ;;=4^C84.40
 ;;^UTILITY(U,$J,358.3,47494,2)
 ;;=^5001641
 ;;^UTILITY(U,$J,358.3,47495,0)
 ;;=C84.41^^209^2346^434
 ;;^UTILITY(U,$J,358.3,47495,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47495,1,3,0)
 ;;=3^Peripheral T-Cell Lymphoma,Head/Face/Neck Nodes
 ;;^UTILITY(U,$J,358.3,47495,1,4,0)
 ;;=4^C84.41
 ;;^UTILITY(U,$J,358.3,47495,2)
 ;;=^5001642
 ;;^UTILITY(U,$J,358.3,47496,0)
 ;;=C84.42^^209^2346^438
 ;;^UTILITY(U,$J,358.3,47496,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47496,1,3,0)
 ;;=3^Peripheral T-Cell Lymphoma,Intrathoracic Nodes
 ;;^UTILITY(U,$J,358.3,47496,1,4,0)
 ;;=4^C84.42
 ;;^UTILITY(U,$J,358.3,47496,2)
 ;;=^5001643
 ;;^UTILITY(U,$J,358.3,47497,0)
 ;;=C84.43^^209^2346^436
 ;;^UTILITY(U,$J,358.3,47497,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47497,1,3,0)
 ;;=3^Peripheral T-Cell Lymphoma,Intra-Abdominal Nodes
 ;;^UTILITY(U,$J,358.3,47497,1,4,0)
 ;;=4^C84.43
 ;;^UTILITY(U,$J,358.3,47497,2)
 ;;=^5001644
 ;;^UTILITY(U,$J,358.3,47498,0)
 ;;=C84.44^^209^2346^432
 ;;^UTILITY(U,$J,358.3,47498,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47498,1,3,0)
 ;;=3^Peripheral T-Cell Lymphoma,Axilla/Upper Limb Nodes
 ;;^UTILITY(U,$J,358.3,47498,1,4,0)
 ;;=4^C84.44
 ;;^UTILITY(U,$J,358.3,47498,2)
 ;;=^5001645
 ;;^UTILITY(U,$J,358.3,47499,0)
 ;;=C84.45^^209^2346^435
 ;;^UTILITY(U,$J,358.3,47499,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47499,1,3,0)
 ;;=3^Peripheral T-Cell Lymphoma,Ing Region/Lower Limb Nodes
 ;;^UTILITY(U,$J,358.3,47499,1,4,0)
 ;;=4^C84.45
 ;;^UTILITY(U,$J,358.3,47499,2)
 ;;=^5001646
 ;;^UTILITY(U,$J,358.3,47500,0)
 ;;=C84.46^^209^2346^437
 ;;^UTILITY(U,$J,358.3,47500,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47500,1,3,0)
 ;;=3^Peripheral T-Cell Lymphoma,Intrapelvic Node
 ;;^UTILITY(U,$J,358.3,47500,1,4,0)
 ;;=4^C84.46
 ;;^UTILITY(U,$J,358.3,47500,2)
 ;;=^5001647
 ;;^UTILITY(U,$J,358.3,47501,0)
 ;;=C84.47^^209^2346^440
 ;;^UTILITY(U,$J,358.3,47501,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47501,1,3,0)
 ;;=3^Peripheral T-Cell Lymphoma,Spleen
 ;;^UTILITY(U,$J,358.3,47501,1,4,0)
 ;;=4^C84.47
 ;;^UTILITY(U,$J,358.3,47501,2)
 ;;=^5001648
 ;;^UTILITY(U,$J,358.3,47502,0)
 ;;=C84.48^^209^2346^439
